Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Nomascus leucogenys genome sequencing

PROVIDER: PRJNA1114679 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR30181577_1.fastq.gz	Fastqsanger.gz
	SRR30181577_2.fastq.gz	Fastqsanger.gz
	SRR30181578_1.fastq.gz	Fastqsanger.gz
	SRR30181578_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Project description:Nomascus leucogenys genome sequencing

| PRJNA955777 | ENA

Nomascus leucogenys

Project description:Nomascus leucogenys principal pseudohaplotype genome sequencing

| PRJNA941361 | ENA

Nomascus leucogenys

Project description:Nomascus leucogenys alternate pseudohaplotype genome sequencing

| PRJNA941360 | ENA

Nomascus leucogenys

Project description:Nomascus leucogenys haplotype 2 genome sequencing

| PRJNA1108629 | ENA

Nomascus leucogenys

Project description:Nomascus leucogenys haplotype 1 genome sequencing

| PRJNA1108630 | ENA

Cichlopsis leucogenys

Project description:Cichlopsis leucogenys

| PRJNA920954 | ENA

Conirostrum leucogenys

Project description:Conirostrum leucogenys

| PRJNA921198 | ENA

Aegithalos leucogenys

Project description:Aegithalos leucogenys

| PRJNA917666 | ENA

A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer.

Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS). Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).

| 2533916 | ecrin-mdr-crc

Nomascus siki

Project description:Nomascus siki overview

| PRJNA251669 | ENA